drugset / Trial / NCT02059564
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus
Timeline
- Start
- 2013-12
- Primary completion
- 2014-10
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efpeglenatide | Peptide | 6 mg | — |
| Subject | Efpeglenatide | Peptide | 16 mg | — |
| Subject | Liraglutide | Peptide | 1.8 mg | — |